Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on continuous ambulatory peritoneal dialysis.

R Khanna, G Wu, S I Vas

    La Ricerca in Clinica E in Laboratorio
    |October 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Twice-daily icodextrin for ultrafiltration failure.

    Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2011
    Same author

    Is professional courtesy dying?

    Canadian Medical Association journal·2010
    Same author

    Know history of CAPD accurately.

    Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2009
    Same author

    Treatment of hyper-IgG4 disease with sequential corticosteroids and tamoxifen - case report and review of the literature.

    Clinical nephrology·2009
    Same author

    Intravenous iron sucrose changes the intraperitoneal homeostasis.

    Blood purification·2009
    Same author

    The effect on renal structure and function of late-life-introduced caloric restriction (CR) in rats.

    International urology and nephrology·2008

    Continuous Ambulatory Peritoneal Dialysis (CAPD) is a proven long-term treatment for end-stage renal disease, with reduced peritonitis rates and emerging challenges like malnutrition. CAPD offers benefits for children and diabetic patients, making it a vital dialysis option.

    Area of Science:

    • Nephrology
    • Internal Medicine

    Background:

    • Continuous Ambulatory Peritoneal Dialysis (CAPD) has evolved into a viable long-term treatment for end-stage renal disease (ESRD).
    • Initial concerns regarding peritonitis have diminished due to improved management and reduced incidence.
    • Chronic complications such as malnutrition and decreased peritoneal ultrafiltration are now primary concerns.

    Purpose of the Study:

    • To evaluate the long-term efficacy and evolving challenges of CAPD in managing end-stage renal disease.
    • To highlight CAPD's role in specific patient populations, including children and diabetics.
    • To underscore the importance of CAPD as a dialysis modality.

    Main Methods:

    • Long-term patient data analysis.
    • Clinical observation of treatment outcomes.

    Related Experiment Videos

  • Review of treatment innovations and their impact.

    • Main Results:

    • CAPD demonstrates successful long-term maintenance for ESRD patients (5+ years).
    • Peritonitis incidence decreased from one episode every 8 months to one every 18 months.
    • CAPD supports better growth in children with ESRD compared to hemodialysis.
    • CAPD shows promise for diabetic ESRD patients, with research into intraperitoneal insulin delivery.

    Conclusions:

    • CAPD is a well-established, non-experimental treatment for ESRD.
    • It offers advantages for specific patient groups and should be available alongside hemodialysis.
    • Nephrologists must be proficient in CAPD to provide optimal individualized patient care.